In late April, HHS made available its study designed to determine the costs and oversight for compounded drugs under Medicare Part B. Based on the lack of existing information related to Medicare and compounded drugs, the study recommends: ● that the Center for Medicaid and Medicare Services (CMS) establish a method to identify Part B claims for compounded drugs ● the possibility of requiring providers to identify the pharmacy that produced a compounded drug, ● and potentially conducting descriptive analyses of Part B claims for compounded drugs. The impact of reimbursement on pharmacy compounding is one of the factors getting more attention as compounding operations come under greater regulatory scrutiny (see the News in Brief May 28, 2014).
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
